The Atopic Dermatitis Learning Center: Riding the Next Wave

Atopic dermatitis (AD) is a chronic inflammatory skin disorder that affects 5% to 30% of children and 1% to 10% of adults globally. It is characterized by recurrent eczematous lesions and intense itch and can have a severe impact on quality of life. Numerous agents that target the immunological mechanism of AD are under investigation in pediatric and adult patients. It is imperative that clinicians have the most recent data to provide optimal outcomes for their patients with AD.

Medscape Education, in collaboration with International Eczema Council (IEC), have developed The Atopic Dermatitis Learning Center: Riding the Next Wave, an innovative parallel clinician and patient education initiative. The goal of this curriculum is to improve the recognition of patients who are candidates for treatment with targeted systemic agents, and improve knowledge of new and emerging JAK inhibitors for AD. The initiative features 6 engaging online clinician interventions that are designed to address these topics. A patient activity also offers a patient perspective on AD, discussing the burden of disease and strategies to discuss them with a clinician.

  • Supported by an independent educational grant from Eli Lilly
  • Developed through the strategic partnership between the International Eczema Council (IEC) and Medscape

 View the Steering Committee featuring IEC leadership. 


Launch the Program

(Participation requires creation of a free Medscape login)